Pfizer wins Warner-Lambert with $84 million acquisition

Article Abstract:

Pfizer Inc. has acquired Warner-Lambert Co. in a deal valued at $84 billion (85.96 billion euros). The acquisition is the largest hostile takeover ever in US history.

---

Pfizer concludes turbulent takeover of Warner-Lambert

Article Abstract:

Pfizer Inc. stated that it finally completed its takeover of Warner-Lambert Co., creating the biggest pharmaceuticals firm in the world, with a projected annual revenue of $31 billion (Euro32 billion). The deal's value was $116 billion based on Monday's closing stock price, reflecting an increase in Pfizer's stock in recent weeks.

Brief Article

---

Speaking now: Pfizer tries to snatch Warner-Lambert from rival AHP; record $82.4 billion bid is aimed at a cash cow and a research bull; letters fall on deaf ears

Article Abstract:

Pfizer Inc launched a hostile takeover of Warner-Lambert Inc for $82.4 billion after Warner-Lambert signed a $72 billion merger agreement with American Home Products Corp. Pfizer is interested in increasing its research and development budget as well as Warner-Lambert's drug, Lipitor.

Statistical Data Included, AHP, Wyeth

Similar abstracts:

• Abstracts: Dealing with imprecise information in group multicriteria decisions: a methodology and a GDSS architecture. Shortest path problems with partial information: models and algorithms for detecting dominance
• Abstracts: Internet sites find it pays to reward visitors; Asian firms give away cash, plane tickets to lure, keep web viewers
• Abstracts: Potent brew: blending of AHP and Warner-Lambert signals deals ahead; European drug companies are seen following path of $70 billion transaction; stocking empty cupboards
• Abstracts: EU Commission tries to draw a road map for digital TV; Microsoft's investment in Telewest raises competition concerns
• Abstracts: NCL seeks higher bid from Carnival; cruise operator's chief willing to weigh offer. Carnival makes bid for P&O Princess to stop rival's deal

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.